RAPT Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for RAPT Therapeutics, Inc. (RAPT) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Operating Activities
Net Income-129.87-116.80-83.84-69.20-52.89-43.00
Depreciation & Amortization1.201.220.751.001.121.33
Stock Based Compensation19.9417.0911.269.958.690.00
Change in Working Capital25.915.500.76-4.302.342.88
Change in Accounts Payable-8.467.343.710.932.390.00
Change in Other Working Capital34.372.34-3.52-1.80-1.010.00
Other Operating Activities-0.482.3410.930.26-0.253.33
Net Cash from Operating Activities-83.30-97.05-70.77-61.03-40.49-35.47
Investing Activities
Capital Expenditures-0.12-1.130.85-0.76-0.400.89
Purchases of Investments-82.22-161.50-44.65-80.59-87.040.00
Sales/Maturities of Investments135.04266.76-44.65-80.59-87.040.00
Net Cash from Investing Activities52.70104.13-45.49-81.35-87.44-0.84
Financing Activities
Common Stock Issued152.011.451.39141.4875.4634.72
Other Financing Activities0.850.000.000.000.000.00
Net Cash from Financing Activities152.851.45131.18141.4875.4649.90
Summary
Net Change in Cash122.268.5314.92-0.89-52.4713.59
Cash at Beginning of Period47.4838.9524.0324.9277.3863.80
Cash at End of Period169.7447.4824.0324.0324.9277.38
Free Cash Flow-83.42-98.17-71.62-61.78-40.89-36.32
Supplemental Disclosures
Income Taxes Paid0.000.000.000.000.990.66